Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
Non Small Cell Lung Cancer
DRUG: ACY-241|DRUG: Nivolumab
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, one to two years|recommended Phase 2 dose (RP2D) of ACY 241 in combination with nivolumab, one to two years
preliminary antitumor activity of ACY 241 in combination with nivolumab, one to two years|Maximum Plasma Concentration [Cmax] of ACY 241 in combination with nivolumab on biomarkers in peripheral blood and tumor tissue, one to two years
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.